Related Experiment Video

Updated: May 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients

Calvin Q Pan1, Ke-Qin Hu, Naoky Tsai

  • 1Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. Cpan11355@yahoo.com.

Antiviral Therapy
|November 27, 2012
PubMed

Insights

Entecavir and tenofovir offer effective long-term treatment for Asian patients with chronic hepatitis B (CHB), achieving significant viral suppression and improving liver health. These oral therapies are crucial for managing CHB in this high-risk population.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Chronic hepatitis B (CHB) affects 400 million globally, with 75% being Asian.
  • Asian patients face higher risks of cirrhosis and hepatocellular carcinoma from CHB.
  • Entecavir and tenofovir are recommended first-line oral therapies for CHB.

Purpose of the Study:

  • To review long-term clinical and real-world data of entecavir and tenofovir in Asian CHB patients.
  • To evaluate the efficacy of these antivirals in both compensated and decompensated liver disease.
  • To inform evidence-based treatment decisions for Asian CHB patients.

Main Methods:

  • Review of clinical long-term studies.
  • Analysis of real-life data.
  • Focus on nucleoside/nucleotide-naive Asian CHB patients.

Main Results:

  • Profound and durable virological suppression achieved with long-term entecavir or tenofovir.
  • Improvements in liver histology and function observed.
  • Consistent efficacy in Asian CHB patients.

Conclusions:

  • Entecavir and tenofovir demonstrate sustained efficacy in treating Asian CHB patients.
  • These therapies are vital for improving long-term outcomes in this demographic.
  • Physicians can use this data for informed first-line therapy and management choices.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...